Targeting of TAMs: can we be more clever than cancer cells?
National Research Tomsk State University · Heidelberg University · +6 more institutions
Abstract
АBSTRACT: With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the…
Citation impact
- FWCI
- 24.86
- Percentile
- 100%
- References
- 439
Authors
3- JKJulia KzhyshkowskaCorresponding
National Research Tomsk State University, Heidelberg University, German Red Cross, University Hospital Heidelberg, Bashkir State Medical University, University Medical Centre Mannheim
- JSJiaxin Shen
Heidelberg University, University Hospital Heidelberg, Second Affiliated Hospital of Zhejiang University
- ILIrina Larionova
National Research Tomsk State University, Tomsk National Research Medical Center, Bashkir State Medical University
Topics & keywords
- Cancer research
- Cancer cell
- Chemistry
- Nanotechnology
- Cancer
- Medicine
- Materials science
- Internal medicine
- Reduced inequalities